Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
Main Authors: | Berruti, Alfredo, Fazio, Nicola, Ferrero, Anna, Brizzi, Maria Pia, Volante, Marco, Nobili, Elisabetta, Tozzi, Lucia, Bodei, Lisa, Torta, Mirella, D’Avolio, Antonio, Priola, Adriano Massimiliano, Birocco, Nadia, Amoroso, Vito, Biasco, Guido, Papotti, Mauro, Dogliotti, Luigi |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996907/ |
Similar Items
-
Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature
by: Bongiovanni, Alberto, et al.
Published: (2014) -
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
by: Koumarianou, Anna, et al.
Published: (2012) -
Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
by: Marinelli, Sara, et al.
Published: (2013) -
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
by: Pietrantonio, Filippo, et al.
Published: (2016) -
Metronomic chemotherapy
by: Maiti, Rituparna
Published: (2014)